期刊文献+

伦理委员会在儿童药物临床试验中的作用探讨 被引量:5

Discussion on the Role of Ethics Committee in Clinical Trials on Children
下载PDF
导出
摘要 我国儿童药品短缺,超说明书用药情况未得到缓解,国家政策大力支持儿童药的研发,药物临床试验需求旺盛,处在良好的发展机遇。儿童生理、心理不成熟,认知水平较低,是临床试验中的弱势群体。伦理委员会需要结合儿童特点,对试验方案、知情同意过程及知情同意书进行审查,及时发现问题并予以纠正,避免将患儿置于不必要的风险中。通过对伦理审查中问题的总结分析,直面伦理挑战,协助研究者、申办方解决项目设计、进展中的问题,提高研究者的积极性;促进成立儿童药物临床试验联盟,定期拟定题目,召开专题讨论会,兼顾培养合格研究者和解决实际发生的问题。 The shortage of children's medicine and off-label medication in China have not been alleviated,national policy has strongly supported the research and development of children's medicine,so that the demand for clinical trials of drugs is strong and is in a good opportunity.Children is a vulnerable group in clinical trials for their physical and psychological immature,low level of cognition.The ethics committee should review the testing program,informed consent and its process in consideration of the characteristics of children,to promptly find out and correct the problems,so as to avoid placing children in unnecessary risk.Through summarizing and analyzing the problems in ethical review,this article is facing ethical challenges,assisting researchers and sponsors to solve problems in project design and progress,improving the enthusiasm of researchers;this article aims to promote the establishment of Children's Clinical Trial Alliance,regularly prepare topics and convene special seminar,which takes into account of training qualified researchers and solving actual problems at the same time.
作者 刘毅 朱彦丽 欧凌 张建民 LIU Yi;ZHU Yanli;OU Ling;ZHANG Jianmin(GCP Office,Children's Hospital,Capital Institute of Pediatrics,Beijing 100021,China;Dept.of Neurology,Children's Hospital,Capital Institute of Pediatrics,Beijing 100021,China)
出处 《中国医院用药评价与分析》 2019年第2期140-142,146,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
基金 北京市属医学科研院所科技发展项目(No.PXM2018_026268_000004) 首都儿科研究所青年科研基金(No.QN-2016-16)
关键词 儿童 伦理委员会 药物临床试验 伦理挑战 Children Ethics committee Clinical trials Ethical challenge
  • 相关文献

参考文献5

二级参考文献20

  • 1田少雷,邵庆翔.药物临床试验与GCP实用指南[M].北京:北京大学医学出版社,2010:302-320.
  • 2The World Medical Association. World Medical Association Declaration of Helsinki [ EB/ OL] . http :// www. wma. net/e/policy/b3, htm.
  • 3Benjamin Freedman, Charles Weijer, Kathleen CranleyGlass. Placebo orthodoxy in clinical research I: Em- pirical and methodological myths. The Journal of Law, Med- icine & Ethics, 1996; 24:243 -251.
  • 4Ezekiel J. Emanuel, Franklin G. Miller. The Eth- ics of Placebo - controlled Trials - A Middle Ground, The New England Journal of Medicine, vol. 345, No. 22 , Sep- tember 20, 2001.
  • 5Lorraine G. Allan, Shepard Siegel. A Signal De- tection Theory Analysis of the Placebo Effect. Evaluation& the Health Professions, vol. 25, no. 4, December 2002 : 410 - 420.
  • 6Mark J Bolland, P Alan Barber, Robert N Dough- ty, et al. Vascular events in healthy older women receiving calcium supplementation: Randomized controlled trial. British Medical Journal, January 2008 ; 336 : 262.
  • 7Jeremy Howick. Questioning the Methodologic Su- periority of ' Placebo' over ' Active' Controlled TriMs. TheAmerican Journal of Bioethics 2009. vol. 9 (9) : 34 - 48.
  • 8Robert Temple, Susan S. Ellenberg. Placebo - Controlled TriMs and Active - Control TriMs in the Evalua- tion of New Treatments, Part 1 : Ethical and Scientific Is- sues. Annals of Internal Medicine, 2000; 133:455 -463.
  • 9周宏灏,袁洪.药物临床试验[M],北京:人民卫生出版社,2011,(3).
  • 10Henry Knowles Beecher. Ethics and clinical re- search. New England Journal of Medicine 1966; 274:1354 - 1360.

共引文献36

同被引文献63

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部